AMERSFOORT, Netherlands, Aug. 27, 2024 /PRNewswire/ — CLEVR today announced the appointment of Tim Claes as its new Chief Executive Officer, effective September 1st, 2024. Tim will replace Jeroen Hanekamp, who will be appointed to the Supervisory Board to ensure an effective transition…
Month: August 2024
– HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine therapy – TOKYO, Aug. 27, 2024 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and…
Le groupe Stock Spirits s’est engagé à réduire ses émissions de gaz à effet de serre (GES) de type 1 et 2 de 42 % et de 20 % minimum de type 3[1] d’ici 2030 dans le cadre de son plan de développement durable révisé. Stratégie fondée sur les piliers suivants : People, Planet, Processes….
• Studie liefert positive Ergebnisse in der ersten von der Industrie geleiteten klinischen Studie zur hereditären Hämorrhagischen Telangiektasie (HHT) • VAD044 zeigte vorteilhafte Sicherheit und Verträglichkeit sowie eine explorative Wirksamkeit bei den wichtigsten Manifestationen der…
GENEVA, Aug. 27, 2024 /PRNewswire/ — As part of their Healthcare investment platform, LIAN Group, an innovative investor and operator known for its healthcare investment in the #1 Swiss dentistry network, Cheeze, announces the acquisition of Scientis, a pioneering Swiss Cosmeceutical…
El ensayo arroja resultados positivos en el primer ensayo clínico dirigido por la industria sobre telangiectasia hemorrágica hereditaria (HHT) VAD044 mostró una seguridad y tolerabilidad favorables, junto con una eficacia exploratoria en las manifestaciones clave de la enfermedad Los…
GENEVA, Aug. 27, 2024 /PRNewswire/ — As part of their Healthcare investment platform, LIAN Group, an innovative investor and operator known for its healthcare investment in the #1 Swiss dentistry network, Cheeze, announces the acquisition of Scientis, a pioneering Swiss Cosmeceutical…
-Stock Spirits Group presenta su nueva estrategia de sostenibilidad y su informe inaugural de sostenibilidad 2023 Stock Spirits Group se ha comprometido a reducir sus emisiones de gases de efecto invernadero (GEI) de alcance 1 y 2 en un 42% y en un mínimo del 20% en el alcance 3[1] para…
Trial delivers positive results in first ever industry-led clinical trial in Hereditary Haemorrhagic Telangiectasia (HHT) VAD044 showed favourable safety and tolerability, together with exploratory efficacy across key manifestations of the disease Ongoing Open Label Extension (OLE) data…
Trial delivers positive results in first ever industry-led clinical trial in Hereditary Haemorrhagic Telangiectasia (HHT) VAD044 showed favourable safety and tolerability, together with exploratory efficacy across key manifestations of the disease Ongoing Open Label Extension (OLE) data…